WDA
IMRX icon

Wendell David Associates’s Immuneering IMRX Stock Holding History

Wendell David Associates’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$75K Hold
15,000
– – 0.01% 154
2026
Q1 		$79K Hold
15,000
– – 0.01% 150
2025
Q4 		$99K Hold
15,000
– – 0.01% 148
2025
Q3 		$105K Buy
+15,000
New +$77.8K 0.01% 148

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Wendell David Associates's IMRX Position: Q2 2026 in Review

Wendell David Associates held its Immuneering (IMRX) position steady in Q2 2026 at 15,000 shares worth $75K. The position accounts for 0.01% of the portfolio, ranked #154.

Wendell David Associates first reported a position in IMRX in Q3 2025 and has held it in 4 quarters since. The position peaked at $105K in Q3 2025. 111 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • Wendell David Associates held 15,000 shares of Immuneering worth $75K as of Q2 2026.
  • Wendell David Associates left its Immuneering share count unchanged in Q2 2026.
  • Immuneering made up 0.01% of Wendell David Associates's portfolio in Q2 2026, its #154 holding.
  • Wendell David Associates first reported a position in Immuneering in Q3 2025 and has held it in 4 quarters since.
  • Wendell David Associates's Immuneering position peaked at $105K in Q3 2025.
  • 111 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Wendell David Associates's 13F filing for Q2 2026, filed 27 Jul 2026.